ATOS (Atossa Therapeutics) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $2.40
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

ATOS
26GF Score
Atossa Therapeutics Inc ATOS
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.40
Price